View Older Stories View More Recent Stories
-
Eli Lilly invests additional $4.5 billion in Indiana manufacturing sites
-
Novo Nordisk reports Q1 earnings on Wednesday: Analysts flag key focus topics
-
Lilly's Omvoh shows sustained disease remission in ulcerative colitis study
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield
-
RBC Capital on Eli Lilly (LLY): 'we think the sell-off is overdone'
-
Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'
-
Guggenheim on Cabaletta Bio (CABA): 'compelling evidence that CAR-T activity can be achieved without preconditioning'
-
Bernstein: We're buyers of weakness in LLY
-
Eli Lilly (LLY) PT Raised to $1,400 at Barclays, 'A remarkably strong quarter...and LLY's only just getting started'
-
Wolfe Research Defending Eli Lilly (LLY) Amid 1.53% Drop: 'Faers For Foundayo Are Unfounded'
-
Why Eli Lilly stock is down 3% today: FDA adverse event data explained
-
Eli Lilly (LLY) PT Lowered to $1,133 at BofA Securities
-
Novo Nordisk rebrands diabetes tablet as Ozempic in US
-
Eli Lilly (LLY) PT Raised to $1,230 at Cantor Fitzgerald
-
Eli Lilly's oral weight loss drug sees over 5,600 prescriptions in third week
-
Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays
-
FDA proposes to exclude semaglutide, tirzepatide from compounding list
-
Lilly surges on earnings beat and raised guidance
-
Eli Lilly & Co. (LLY) Tops Q1 EPS by $1.58, Beats on Revenue; Offers Strong Guidance
-
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put into quarter results
-
Eli Lilly Q1 earnings preview: analysts eye outlook for obesity drugs
-
Eli Lilly & Co. (LLY) call put ratio 1.1 calls to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.5 calls to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put into quarter results
-
Eli Lilly (LLY) PT Lowered to $$1,058 at Leerink Partners
-
AI is starting to impact the pharma sector — These 2 stocks are seen as NT winners
-
Morgan Stanley Comments on Eli Lilly (LLY) Amid Premarket Volatility
-
Eli Lilly & Co. (LLY) shares trade lower on weak Foundayo launch
-
Hims & Hers expands platform to include Eli Lilly weight loss medications
-
Bernstein: Potential for Beat to Drive Eli Lilly (LLY) Stock
-
Rigel Pharmaceuticals regains rights as Lilly terminates license deal
-
Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
-
Eli Lilly and Novo Nordisk shares fall as CVS opts out of Medicare obesity drug coverage
-
CVS Health Opts Out Of Medicare Obesity Drug Coverage Model
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Bernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)
-
RBC Capital on Eli Lilly (LLY): Kelonia acquisition payment 'may appear full,' but strategically justified
-
RBC on Legend Biotech Corp. (LEGN): 'We Think Shares Remain Undervalued'
-
Eli Lilly & Co. (LLY) nears deal to acquire Kelonia Therapeutics - WSJ
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
Guggenheim Reiterates Buy Rating on Eli Lilly (LLY)
-
Leerink Partners now expects Eli Lilly's (LLY) Foundayo in diabetes to be approved in 2H26
-
Walmart expands weight management services with virtual care platform
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly to acquire CrossBridge Bio for up to $300 million
-
Leerink stays Outperform on Eli Lilly (LLY) after Jaypirca Ph3 results
-
Lilly's Jaypirca shows positive results in blood cancer trial
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
Eli Lilly & Co. (LLY) call put ratio 2 calls to 1 put as share price down 1.7%
-
RBC Capital 'Expecting GLP-1 Sales Strength' for Eli Lilly (LLY)

